BioSpace News Archive

Deals

Juno Pharmaceuticals Acquires Omega Laboratories, Propelling Canada’s Pharmaceutical Industry Forward

Today, Juno Pharmaceuticals Canada announced the acquisition of Omega Laboratories (“Omega”), one of Canada’s largest domestic specialty injectable pharmaceutical manufacturers.

May 15, 2023
·
3 min read
Business

Inhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period Activity

Inhibikase Therapeutics, Inc. today reported financial results for the first quarter ended March 31, 2023 and highlighted recent developments.

May 15, 2023
·
10 min read
Business

CNS Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update

CNS Pharmaceuticals, Inc. today reported its financial results for the quarter ended March 31, 2023 and provided a clinical update of its anti-cancer drug candidate currently in development for the treatment of primary and metastatic brain and CNS cancer.

May 15, 2023
·
6 min read
Business

AIM ImmunoTech Reports First Quarter Financial Results and Provides Pipeline Update

AIM ImmunoTech Inc. reported its financial results for the first quarter 2023 and provided a business update.

May 15, 2023
·
4 min read
Biotech Beach

ARS Pharmaceuticals Highlights Progress and Reports First Quarter 2023 Financial Results

ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis, today highlighted recent progress and reported first quarter 2023 financial results.

May 15, 2023
·
10 min read
AnHorn Medicines Presents Research of Novel Protein Degrader for Topical Use at ISID Meeting 2023

AnHorn Medicines presented its potential first-in-class protein degrader program, AH-001, at the First International Societies for Investigative Dermatology Meeting (ISID 2023) in Tokyo.

May 15, 2023
·
2 min read
U.S. Food and Drug Administration Issues Complete Response Letter for Byondis’ [Vic-]Trastuzumab Duocarmazine

Byondis B.V., an independent, Dutch clinical-stage biopharmaceutical company creating precision medicines, today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) for the Biological License Application (BLA) for [vic-]trastuzumab duocarmazine (SYD985).

May 15, 2023
·
2 min read
Business

Neurelis Announces New Roles for Top Executives to Advance Clinical and Strategic Initiatives and Position for Future Growth

Neurelis, Inc., announced the promotion of Adrian L. Rabinowicz, MD, to Chief Medical Officer and the establishment of a new leadership position of Senior Vice President, Strategic Initiatives for Enrique Carrazana, MD.

May 15, 2023
·
8 min read
Genetown

Boston Scientific to Participate in Bernstein’s 39th Annual Strategic Decisions Conference

Boston Scientific Corporation (NYSE: BSX) will participate in Bernstein’s 39th Annual Strategic Decisions Conference on Wednesday, May 31, 2023.

May 15, 2023
·
1 min read
Deals

PARI acquires Nortev, the manufacturer of the equine inhaler Flexineb®

PARI, manufacturer of medical devices and pharmaceuticals in the field of respiratory and inhalation, today announced the acquisition of the Irish company Nortev.

May 15, 2023
·
3 min read